Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Dec;127(12):2118-2124.
doi: 10.1038/s41416-022-01982-5. Epub 2022 Oct 12.

Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment

Thi-Van-Trinh Tran  1   2   3 , Carole Rubino  4   5   6 , Rodrigue Allodji  7   8   9 , Milena Andruccioli  10 , Stéphane Bardet  11 , Ibrahima Diallo  7   8   9 , Massimo Dottorini  12 , Jérome Garsi  7   8   9 , Per Hall  13   14 , Michel Henry-Amar  15 , Stephanie Lamart  16 , Françoise Le Thai  17 , Stefan Lönn  18 , Marcel Ricard  19 , Claire Schvartz  20   21 , Martin Schlumberger  22 , Neige Journy  7   8   9 , Florent de Vathaire  23   24   25
Affiliations

Breast cancer risk among thyroid cancer survivors and the role of I-131 treatment

Thi-Van-Trinh Tran et al. Br J Cancer. 2022 Dec.

Abstract

Background: Female thyroid cancer survivors are more likely to have a higher risk of breast cancer compared to the general population, and the underlying causes are yet to be understood. The potential role of I-131 treatment on this association remains controversial.

Methods: We pooled individual data of women who were treated for differentiated thyroid cancer from 1934 to 2005 in France, Italy and Sweden. Standardized incidence ratios (SIRs) for breast cancer were estimated by comparison with age, sex and calendar-year expected values of the general population in each country. We estimated breast cancer risk in relation to I-131 treatment using time-dependent Poisson models.

Results: Of 8475 women (mean age at diagnosis: 45 years, range 2-90 years), 335 were diagnosed with breast cancer [SIR = 1.52, 95% confidence interval (CI): 1.36-1.69] during a median follow-up time of 12.7 years since diagnosis. Overall, breast cancer risk did not differ between women treated or not with I-131 (relative risk=1.07, 95% CI 0.84-1.35). However, breast cancer risk increased with increasing cumulative I-131 activity, without significant departure from linearity (excess relative risk per 100 mCi=17%, 95% CI: 2% to 38%). The higher risk associated with a cumulative I-131 activity of ≥100 mCi and ≥400 mCi was translated into 4 (95% CI -4 to 13) and 42 (95% CI -8 to 93) excess breast cancer cases per 10,000 person-years, respectively.

Conclusions: An elevated risk was observed for the highest cumulative administered activity (>=400 mCi), and a significant dose-dependent association was observed among thyroid cancer survivors who were treated with I-131. However, overall, I-131 treatment might only explain partly the increase in breast cancer risk among female thyroid cancer survivors.

PubMed Disclaimer

Conflict of interest statement

The authors declare no competing interests.

Figures

Fig. 1
Fig. 1. Flowchart of the study.
Flowchart describing the exclusions in the three European cohorts (France, Italy and Sweden).
Fig. 2
Fig. 2
Cumulative breast cancer incidence among thyroid cancer survivors by cumulative activities of I-131.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

References

    1. Ferlay J, Ervik M, Lam F, Colombet M, Mery L, Piñeros M, et al. Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer, https://gco.iarc.fr/today. Accessed 5 January 2020.
    1. Kitahara CM, Sosa JA. The changing incidence of thyroid cancer. Nat Rev Endocrinol. 2016;12:646–53. doi: 10.1038/nrendo.2016.110. - DOI - PMC - PubMed
    1. Li M, Dal Maso L, Vaccarella S. Global trends in thyroid cancer incidence and the impact of overdiagnosis. Lancet Diabetes Endocrinol. 2020;8:468–70. doi: 10.1016/S2213-8587(20)30115-7. - DOI - PubMed
    1. Gilliland FD, Hunt WC, Morris DM, Key CR. Prognostic factors for thyroid carcinoma. A population-based study of 15,698 cases from the Surveillance, Epidemiology and End Results (SEER) program 1973-1991. Cancer. 1997;79:564–73. doi: 10.1002/(SICI)1097-0142(19970201)79:3<564::AID-CNCR20>3.0.CO;2-0. - DOI - PubMed
    1. Reiners C, Schneider R, Platonova T, Fridman M, Malzahn U, Mäder U, et al. Breast cancer after treatment of differentiated thyroid cancer with radioiodine in young females: what we know and how to investigate open questions. review of the literature and results of a multi-registry survey. Front Endocrinol. 2020;11:381. doi: 10.3389/fendo.2020.00381. - DOI - PMC - PubMed